A landmark study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has revealed something extraordinary. Women taking GLP-1 drugs like Ozempic and Wegovy were roughly 30% less likely to develop breast cancer – a finding that is reshaping how doctors think about these blockbuster weight-loss medications.
What the Study Found
Researchers at Penn Medicine analyzed electronic health records from 111,646 women aged 45 to 80, all with a BMI of 25 or higher, who underwent breast imaging between January 2022 and June 2025. The results were striking. Women using GLP-1 medications had 35.1% lower odds of developing breast cancer in the full study group, and 30.5% lower odds in the carefully matched comparison group.
The findings were published in JCO Oncology Practice – one of the most respected oncology journals in the world.
Key Numbers From the Penn Medicine Study
111,646 women studied – all aged 45-80 with BMI of 25 or higher, from Penn Medicine health system
35.1% lower odds of breast cancer in GLP-1 users across the full study cohort
30.5% lower odds in the matched comparison group – the more statistically robust result
Clinical trial now planned to confirm whether the protective effect is real and consistent
Why Might Ozempic Protect Against Breast Cancer?
Researchers have three working theories, and none of them are far-fetched.
Reduced body fat lowers estrogen. Excess body fat produces estrogen, and estrogen fuels roughly 70% of all breast cancers. When GLP-1 drugs drive significant weight loss, they may be removing one of the most powerful drivers of hormone-sensitive tumours. Less fat means less circulating estrogen – and less fuel for cancer cells to grow.
Reduced systemic inflammation. Obesity is a state of chronic, low-grade inflammation throughout the body. GLP-1 receptors are found not just in the gut and brain, but in immune cells throughout the body. By reducing inflammation, these drugs may create a less hospitable environment for cancer to take hold.
A direct GLP-1 receptor effect. Some researchers believe semaglutide may have a direct anti-tumour action, independent of weight loss entirely. Animal studies have shown promising signals. This is still under investigation, but it adds a fascinating third dimension to what these drugs may be doing.
Who Was Studied – And Why That Matters
The study focused on women aged 45 to 80 with a BMI of 25 or higher – a group at elevated risk for breast cancer precisely because of excess body weight and the estrogen it generates after menopause. The researchers chose this group deliberately – they wanted to see whether weight-loss drugs could shift outcomes in a high-risk population.
The study was observational, which means researchers tracked what happened to women already taking GLP-1 drugs – it was not a randomised controlled trial. This is an important distinction. We cannot yet say with certainty that GLP-1 drugs cause the reduction in cancer risk. However, the sample size of over 111,000 women and the consistency of findings across different analyses make this very difficult to dismiss.
What Doctors Are Saying
The findings were presented at ASCO 2026 – one of the world’s most respected oncology conferences. Oncologists who reviewed the study called the signal compelling and noted that it adds to a fast-growing body of evidence linking GLP-1 drugs to benefits far beyond weight loss and blood sugar control.
A dedicated clinical trial is now being planned to test whether GLP-1 drugs can be formally used as a cancer prevention strategy. If confirmed, this would represent a historic expansion of how we think about and prescribe these medications.
What This Means If You Are Already on Ozempic or Wegovy
If you are already taking a GLP-1 drug for diabetes or weight management, this study is reassuring news. You may be receiving a cancer-protective benefit on top of the metabolic and cardiovascular benefits you already know about. Talk to your doctor about what this finding means for your personal health picture.
If you are not on a GLP-1 drug, this is not yet a reason to start one purely for cancer prevention. These are prescription medications with real side effects, and the evidence is still preliminary. But it is worth discussing with your doctor if you are in a higher-risk group.
Supporting Healthy Metabolism Naturally
Whether or not you are on a GLP-1 drug, maintaining a healthy weight remains one of the most powerful evidence-based strategies a woman can use to reduce breast cancer risk. Exercise, a fibre-rich diet, limiting alcohol, and managing body fat all play measurable roles in cancer prevention.
For those looking to support their metabolic health with consistent supplementation, a high-quality weight management supplement can help complement dietary changes. Research suggests green coffee extract supports healthy metabolism and fat oxidation when used alongside a balanced diet.
Recommended: Metabolism Support Supplement
If you are working on reaching a healthier weight and want metabolic support, I recommend checking out this well-rated green coffee extract supplement on Amazon India. Consistent use alongside a healthy diet can support your long-term weight goals. Check it out on Amazon.in
The Bottom Line
A study of 111,000 women found that GLP-1 drugs like Ozempic and Wegovy were associated with a 30-35% reduction in breast cancer risk. The mechanism is not yet fully confirmed, and a clinical trial is now planned. But the signal is strong enough that oncologists worldwide are paying close attention.
This is one more piece of evidence that GLP-1 drugs may be among the most consequential medicines of our generation – and we may still only be at the beginning of understanding what they can do.
Read the full breakdown at medimadad.com, and share this with every woman in your life who should know about it.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Dr. Ajit Kumar, MD (Medicine) | IMA Lifetime Member | Editorial Board Member, International Journal of Diabetes and Endocrinology (IJDE). Always consult your healthcare provider before making any changes to your medication or health routine.
📖 Related Articles